Opaleye Management’s Steady Buying at Grace Therapeutics Signals Quiet Confidence in its Orphan‑Drug Pipeline
Opaleye Management’s recent steady buying of Grace Therapeutics shares shows confidence in its orphan‑drug pipeline, hinting at potential upside without market panic.
3 minutes to read